Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

378 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
Sabry W, Le Blanc R, Labbé AC, Sauvageau G, Couban S, Kiss T, Busque L, Cohen S, Lachance S, Roy DC, Roy J. Sabry W, et al. Among authors: le blanc r. Biol Blood Marrow Transplant. 2009 Aug;15(8):919-29. doi: 10.1016/j.bbmt.2009.04.004. Epub 2009 Jun 10. Biol Blood Marrow Transplant. 2009. PMID: 19589481 Free article. Clinical Trial.
Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation.
Ahmad I, LeBlanc R, Cohen S, Lachance S, Kiss T, Sauvageau G, Roy DC, Busque L, Delisle JS, Bambace N, Bernard L, Sabry W, Roy J. Ahmad I, et al. Bone Marrow Transplant. 2016 Apr;51(4):529-35. doi: 10.1038/bmt.2015.319. Epub 2015 Dec 21. Bone Marrow Transplant. 2016. PMID: 26691426 Clinical Trial.
Newly diagnosed multiple myeloma patients treated with tandem auto-allogeneic stem cell transplant have better overall survival with similar outcomes at time of relapse compared to patients who received autologous transplant only.
LeBlanc R, Claveau JS, Ahmad I, Delisle JS, Bambace N, Bernard L, Cohen S, Kiss T, Lachance S, Landais S, Roy DC, Sauvageau G, Roy J. LeBlanc R, et al. Clin Transplant. 2020 Dec;34(12):e14099. doi: 10.1111/ctr.14099. Epub 2020 Oct 22. Clin Transplant. 2020. PMID: 32981146
Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study.
LeBlanc R, Ahmad I, Terra R, Boudreault JS, Ogez D, Lamore K, Delisle JS, Bambace N, Bernard L, Cohen S, Kiss T, Lachance S, Landais S, Lemieux-Blanchard É, Sauvageau G, Sebag M, Roy DC, Roy J. LeBlanc R, et al. Bone Marrow Transplant. 2022 Feb;57(2):252-260. doi: 10.1038/s41409-021-01532-2. Epub 2021 Nov 29. Bone Marrow Transplant. 2022. PMID: 34845367 Clinical Trial.
Bortezomib Maintenance After Allogeneic Transplantation in Newly Diagnosed Myeloma Patients Results in Decreased Incidence and Severity of Chronic GVHD.
Claveau JS, LeBlanc R, Ahmad I, Delisle JS, Cohen S, Kiss T, Bambace NM, Bernard L, Lachance S, Roy DC, Sauvageau G, Veilleux O, Roy J. Claveau JS, et al. Transplant Cell Ther. 2023 Jan;29(1):44.e1-44.e9. doi: 10.1016/j.jtct.2022.10.022. Epub 2022 Nov 2. Transplant Cell Ther. 2023. PMID: 36334654 Free article.
378 results